University of California

Urigen N.a.

Other

Parsons, C. Lowell

C Lowell Parsons

Daniel Vickery

Christopher P Meenan

William J Garner

Paul Zupkas

Michael Flashner

Amie E Franklin

The present invention provides a method for treating and/or ameliorating a disorder of the lower urinary tract, comprising administering a composition comprising a glucagon like peptide 2 (GLP-2) receptor agonist to a patient in need thereof in an amount sufficient to treat and/or ameliorate the disorder of the lower urinary tract.

Treatment of lower urinary tract epithelium with glucagon like peptide 2

The present invention relates to a disorder of the lower urinary tract, and in particular, reducing the symptoms (including treatment) of interstitial cystitis in vivo. In a preferred embodiment, the present invention relates to treatment formulations and methods for reducing interstitial cystitis in patients.

Interstitial therapy for immediate symptom relief and chronic therapy in interstitial cystitis

Transluminal drug delivery method and device embodiments can include a urethral suppository formulated to prevent or treat diseases of the urethra and surrounding organs, such as interstitial cystitis or urethritis, by enhancing the absorption of a therapeutic agent of the suppository into body tissues without adversely affecting the natural defense mechanisms of these tissues. Adverse effects on the glycosaminoglycan (GAG) barrier can be mitigated or eliminated by the presence of a suitable polysaccharide in the suppository.

Transluminal drug delivery methods and devices

Growing community of inventors

Henderson, NV, United States of America

C Lowell Parsons